// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Inhibition of myeloid cell leukaemia 1 (MCL1) overcomes bromodomain and extra‐terminal (BET) inhibition resistance in acute myeloid leukaemia (AML) cells

E. Ladikou - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Analysis of treatment patterns and outcomes for patients with therapy‐related acute myeloid leukaemia and acute myeloid leukaemia with myelodysplasia‐related changes diagnosed in England between 2011–2016 using hospital episode statistics®

A. Legg - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Vidaza

Synergistic inhibition of FLT3‐ITD acute myeloid leukaemia cell growth in vitro using combination of FLT3 inhibitor quizartinib and standard of care chemotherapeutic agent cytarabine

S. Darici - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

quizartinib

Whose choice is it anyway? A multi‐national and multi‐stakeholder perspective on shared treatment decision making in older adults with acute myeloid leukaemia

N. Russell - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Acute myelocytic leukemia

N/A

Genetic and genomic characterisation of older adults with acute lymphoblastic leukemia treated on the UKALL14 and UKALL60 + clinical trials

T. Creasey - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Findings from the UK NEQAS for leucocyte immunophenotyping haematological malignancy bone marrow aspirate assessment programme

A. Whitby - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Optimising diagnosis and management of acute chest syndrome in sickle cell disease through a full cycle audit of adherence to the BSH guidelines

T. Westerman - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Acute chest syndrome

Hydroxycarbamide

Graphical description of performance characteristics of laboratories and assays using data from the UK NEQAS for haematinics

F. Mackenzie - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A review of bleeding events associated with anticoagulants that have led to patient harm with a primary focus on transitions of care

D. S. Rata Mohan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Bolus: education delivered stat podcast

S. Thomas - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

On arterial blood gas: how can we reduce avoidable sampling?

A. Pons - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

N/A

‘Guidelines and chips’: food for thought in supporting trainees

A. Aggarwal - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Diffuse idiopathic skeletal hyperostosis

Methadone hydrochloride

CDx report program – assessment of the current reporting practice for haemato‐oncology companion diagnostics (CDx) markers in the UK and Ireland

P. Evans - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methadone hydrochloride

The Haematology Summit 2014–2019: evolution of a national medical education programme

N. Prynn - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Education and training of healthcare scientists in haematology ‐ fit for the future?

S. O'Connor - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A different kind of OOPE, volunteering to improve haematology services in Malawi

M. Player - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Castleman disease

Methadone hydrochloride

Haembase: improving the quality of a free open access medical education resource targeted at haematologists in training

T. Bull - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methadone hydrochloride

Serum ferritin and transferrin saturation are not reliable predictors of mild to moderate iron overload detected by R2‐MRI in patients with non‐HFE mutated hyperferritinaemia

S. Patel - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Transfusion-dependent β-thalassemia

Ferriscan

Suggestions for the monitoring and follow up of patients with systemic mastocytosis based on a single centre tertiary experience

M. Alley - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Mastocytosis

N/A

A study of Telomere length as a predictor for multi‐system complications and outcomes in bone marrow failure disorders

S. Gandhi - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Copyright © 2026. QuantiNova All rights reserved